The toxicity of these compounds has yet to be tested in humans, while the calculated 2xIC50 of venetoclax for hepsin is within the concentration range tested in chronic lymphocytic leukemia cells (Anderson et al., 2016). The gene discussed is HPN; the disease is B-cell chronic lymphocytic leukemia.